These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Immunological study on circulating murine osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF): possible role of OPG/OCIF in the prevention of osteoporosis in pregnancy. Yano K; Shibata O; Mizuno A; Kobayashi F; Higashio K; Morinaga T; Tsuda E Biochem Biophys Res Commun; 2001 Oct; 288(1):217-24. PubMed ID: 11594776 [TBL] [Abstract][Full Text] [Related]
11. Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. Franchimont N; Reenaers C; Lambert C; Belaiche J; Bours V; Malaise M; Delvenne P; Louis E Clin Exp Immunol; 2004 Dec; 138(3):491-8. PubMed ID: 15544627 [TBL] [Abstract][Full Text] [Related]
12. Assessment of a serum assay for quantification of abdominal aortic calcification. Clancy P; Oliver L; Jayalath R; Buttner P; Golledge J Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2574-6. PubMed ID: 17053174 [No Abstract] [Full Text] [Related]
13. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients. Kraj M; Owczarska K; Sokołowska U; Centkowski P; Pogłód R; Kruk B Arch Immunol Ther Exp (Warsz); 2005; 53(5):454-64. PubMed ID: 16314829 [TBL] [Abstract][Full Text] [Related]
14. Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. Shin JY; Shin YG; Chung CH Diabetes Care; 2006 Jul; 29(7):1664-6. PubMed ID: 16801598 [No Abstract] [Full Text] [Related]
15. Osteoprotegerin serum levels in multiple myeloma and MGUS patients compared with age- and sex-matched healthy controls. Corso A; Dovio A; Rusconi C; Sartori ML; Klersy C; Varettoni M; Mangiacavalli S; Zappasodi P; Ventura M; Angeli A; Lazzarino M Leukemia; 2004 Sep; 18(9):1555-7. PubMed ID: 15241438 [No Abstract] [Full Text] [Related]
16. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Ziolkowska M; Kurowska M; Radzikowska A; Luszczykiewicz G; Wiland P; Dziewczopolski W; Filipowicz-Sosnowska A; Pazdur J; Szechinski J; Kowalczewski J; Rell-Bakalarska M; Maslinski W Arthritis Rheum; 2002 Jul; 46(7):1744-53. PubMed ID: 12124857 [TBL] [Abstract][Full Text] [Related]
17. Serum osteoprotegerin levels in healthy controls and cancer patients. Lipton A; Ali SM; Leitzel K; Chinchilli V; Witters L; Engle L; Holloway D; Bekker P; Dunstan CR Clin Cancer Res; 2002 Jul; 8(7):2306-10. PubMed ID: 12114435 [TBL] [Abstract][Full Text] [Related]
18. The relationship between insulin resistance assessed by HOMA-IR and serum osteoprotegerin levels in obesity. Ugur-Altun B; Altun A; Gerenli M; Tugrul A Diabetes Res Clin Pract; 2005 Jun; 68(3):217-22. PubMed ID: 15936463 [TBL] [Abstract][Full Text] [Related]
19. Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. Skoumal M; Kolarz G; Haberhauer G; Woloszczuk W; Hawa G; Klingler A Rheumatol Int; 2005 Nov; 26(1):63-9. PubMed ID: 15889303 [TBL] [Abstract][Full Text] [Related]
20. Circulating osteoprotegerin is not removed through haemodialysis membrane. Kazama JJ; Kato H; Sato T; Shigematsu T; Fukagawa M; Iwasaki Y; Gejyo F Nephrol Dial Transplant; 2002 Oct; 17(10):1860-1. PubMed ID: 12271009 [No Abstract] [Full Text] [Related] [Next] [New Search]